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ABSTRACT 
Objective: To estimate the cost of therapy of tuberculosis patients registered under DOTS program in the treatment of tuberculosis.  
Methods: A prospective observational study was conducted over a period of nine months in the Pulmonary Department of Bharati hospital and 
Research centre, Pune. 97 patients registered under RNTCP between August 2014 and April 2015, were interviewed at two time points: one at the 
time of first hospital visit and second on the completion of treatment. During the interview, information relating to various costs such as direct (out 
of pocket) and indirect cost was collected.  
Results: The mean total cost for Pulmonary tuberculosis treatment was found to be/5474.7 ($85.4), Extra pulmonary was/10574.8 ($164.9) and 
Pulmonary and Extra pulmonary was/14638.5 ($228.3) respectively. Out of total cost the cost incurred by the patients for the hospital stay and 
diagnosis (i.e. tuberculosis detection) has the maximum expenditure cost which was 90.4 % for pulmonary tuberculosis, 77.2% extra pulmonary 
and 72.5% pulmonary and extra pulmonary. About 39.2 % of patients and their care takers lost work days. 52.0% pulmonary patients, 68.4% extra-
pulmonary and 66.7 % pulmonary and extra-pulmonary patients had decreased earning ability due to illness.  
Conclusion: The maximum cost is incurred for diagnosis and hospital stay in tuberculosis patients. Though DOTS strategy can help to reduce cost, 
achieve effective cure and save life of TB patients, still patients need to spend for other investigations and other drugs. 
Keywords: Tuberculosis, DOTS, Patient cost. 
 
INTRODUCTION 
Tuberculosis (TB) is one of the leading causes of mortality among 
infectious disease worldwide and has an enormous economic impact 
on many countries [1]. India is the highest TB burden country 
accounting for one fifth of the global incidence of TB. In 2013, an 
estimated nine million people developed TB and 1.5 million died from 
the disease, 360,000 of whom were HIV-positive [2]. India accounts for 
fourth of the global burden of TB and 29% of global mortality due to 
TB [3]. The disease is more prevalent in the productive age group of 
15-54 y which causes an economic burden on the individual’s 
household when they fall sick.  
The disease is also a major barrier to social and economic 
development. An estimated 100 million workdays or three to four 
months of work time are lost due to illness, affecting potential earning 
of 20-30% of annual household income. Society and the country incur 
a huge cost due to TB nearly $3 billion in indirect costs and $300 
million in direct cost [4]. 
Tuberculosis is treatable and curable with timely diagnosis and 
adherence to the prescribed course of treatment. The launch of the 
Directly Observed Treatment Short-course (DOTS) strategy by the 
World Health Organization (WHO) was expected to control 
tuberculosis i.e. Substantially reduce the number of new TB cases by 
improving case detection and cure rates of patients. RNTCP provides 
DOTS treatment to registered patients free of cost throughout the 
country, a substantial portion of the costs still fall on the patients 
and their families. A thorough understanding of the costs associated 
with TB diagnosis and treatment is important to develop 
interventions to reduce that economic burden on patients. The 
present study was to estimate the direct, indirect and total 
(diagnosis and treatment) costs to patients on account of 
tuberculosis treated in DOTS programme. 
MATERIALS AND METHODS 
A prospective observational study was conducted over a period of 
nine months from August 2014 to April 2015 in Pulmonary 
Department of Bharati hospital and Research centre, Pune. 97 
patients registered under RNTCP between August 2014 and April 
2015, were interviewed. Pulmonary, extra-pulmonary and 
pulmonary and extra-pulmonary TB cases receiving DOTS therapy 
were included in the study. Patients who were not willing to 
participate in the study and HIV patients with tuberculosis were 
excluded from the study. Patients under inclusion criteria were 
selected and their informed consent was taken for the study. TB 
patients and their supporters (relatives) were interviewed at two 
time points: one at the time of hospital visit and second on the 
completion of treatment. During the interview, information relating 
to various costs such as direct (out of pocket) and indirect cost was 
collected. Direct costs are defined as Consultation fees and money 
spent on investigations and drugs were classified as medical 
expenditure.  
Money spent on travel, lodging, special food and expenditure 
incurred for persons accompanying the patient was classified as 
nonmedical expenditure. Indirect costs were classified as loss of 
wages due to illness, decreased earning ability due to illness or long 
term disability that necessitated change in type of work. Total cost 
includes the expenditure incurred for tuberculosis detection and 
treatment under direct and indirect costs. The cost was calculated in 
terms of Indian rupees and US dollars (exchange rate during study 
period: ($1 US= Rs. 64.11). Total treatment cost was calculated for 
only those patients who completed treatment successfully. Patients 
with treatment outcomes such as defaulted, migrated, transferred 
out and died were not available and hence excluded. Patients who 
had failed and were on re-treatment were not considered for this 
analysis. The cost of therapy data was analyzed by using standard 
deviations. 
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Out of 97 patients studied, 43 (44.3%) were males and 54 (55.7%) 
were females; the majority of patients 60 (61.8%) were in the age 
group of 15-34 y. 68(70.1%) patients were from urban area. Annual 
family income of 8 (8.2 %) patients ranged between 50,000-1, 
20000 rupees. 15 (15.5%) patients were illiterate and 36 patients 
(33.0%) were unemployed. 
  
Table 1: Sociodemography of tuberculosis patients (n=97) 
Characteristics Number of patients Total Number 
Of patients (%) Pulmonary  Extra-pulmonary Pulmonary and Extra-pulmonary  
Gender 
Male  26 14 3 43 (44.3) 
Female 22 29 3 54 (55.7) 
Age group 
5-14 - 3 1 4 (4.1) 
15-24 14 14 1 29 (29.9) 
25-34 12 17 2 31 (31.9) 
35-44 5 4 - 9 (9.3) 
45-64 14 4 1 19 (19.6) 
>64 3 1 1 5 (5.1) 
Place of residence     
Rural 14 12 3 29 (29.9) 
Urban  34 31 3 68 (70.1) 
Education     
None 8 6 1 15 (15.5) 
Primary 14 11 2 27 (27.8) 
High school 19 17 1 37 (38.1) 
University 7 9 2 18 (18.5) 
 Annual Income     
50,000-1,20,000 4 3 1  8 (8.2) 
1,21,000-2,20,000 19 13 1  33 (34.0) 
2,21,000-3,20,000 18 16 -  34 (35.1) 
>3,20,000 7 11 4  22 (22.7) 
Employment status     
Employed 21 16 3 40 (41.2) 
Unemployed 14 16 2 32 (33.0) 
Retired 4 1 - 5 (5.1) 
Student 9 10 1 20 (20.6) 
History of hospitalization     
Yes 13 19 6 38 (39.1) 
No 35 24 0 59 (60.9) 
49.4 % had pulmonary tuberculosis, 44.3 % had extra pulmonary tuberculosis and 6.2 % had pulmonary and extra-pulmonary tuberculosis.  
 
Table 2: Direct, indirect, and total costs incurred by patients during tuberculosis treatment 
Types of tuberculosis Direct cost/($) Indirect cost/($) Total cost/($) 
Medical Cost Non Medical Cost Mean/($) SD Mean/($) SD 
Mean/($) SD Mean/($) SD 
Pulmonary 4451.8($69.4) 4397.2 270.6 ($4.2) 1089.9 752.0($11.7) 1621.6 5474.4 ($85.4) 4239.6 
Extrapulmonary 9116.1($ 142.2) 2864.8  614.8($9.6) 1552.3  843.9($13.2) 1937.6  10574.8($164.9) 3612.5 
Pulmonary and extrapulmonary 12496.6($194.9) 2742.6 1306.6($20.4) 656.4 835.3($13.0) 2181.4 14638.5($228.3) 3313.6 
The cost incurred by the patients for the hospital stay and diagnosis (i.e. tuberculosis detection) has the maximum expenditure compared to other 
medical cost which was 90.4 % for pulmonary tuberculosis, 77.2% extra pulmonary and 72.5% pulmonary and extra pulmonary. The expenditure for 
lab investigation was 747.8 ($11.7) for pulmonary, 1879.1 ($29.3) for extra pulmonary and for 3050.0($47.6) extra pulmonary and pulmonary patients. 
The X-ray examination expenses were 1047.9 ($16.3) for pulmonary, 1133.7 ($17.7) extra pulmonary and 1291.6($20.1) for extra pulmonary and 
pulmonary tuberculosis. The expense for other medication was 359.4 ($5.6) for pulmonary, 454.7 ($7.1) for extra pulmonary and 1050.0 ($16.4) for 
extra pulmonary and pulmonary patients. The cost for food and travel during diagnosis (i.e. direct non medical cost) is listed in table 3. 
 
DISCUSSION 
The study estimated the average total costs incurred by pulmonary, 
extra-pulmonary and pulmonary and extra pulmonary tuberculosis. 
The mean total cost for Pulmonary tuberculosis treatment was 
found to be/5474.4 ($85.4), Extra pulmonary was/10574.8($164.9) 
and Pulmonary and Extra pulmonary was/14638.5 ($228.3). 
However, the encouraging finding is that the estimated mean total 
cost in our study was less as compared to earlier study [5]. Our 
results suggest that DOTS program is cost saving for patients.  
The cost incurred by the patients for the hospital stay and diagnosis (i.e. 
tuberculosis detection) has the maximum expenditure compared to 
other medical cost which was 90.4 % for pulmonary tuberculosis, 77.2% 
extra-pulmonary and 72.5% pulmonary and extra-pulmonary. Our 
results suggest that TB diagnosis and treatment posed a significant 
economic burden on patients in terms of cost. The expenditure for lab 
investigation was/747.8 ($11.7) for pulmonary,/1879.1 ($29.3) for 
extra-pulmonary and for/3050.0($47.6) extra-pulmonary and 
pulmonary patients. The X-ray examination expenses were/1047.9 
($16.3) for pulmonary,/ 1133.7 ($17.7) extra-pulmonary and/1291.6 
($20.1) for extra-pulmonary and pulmonary tuberculosis. The expense 
for other medication was/359.4 ($5.6) for pulmonary,/454.7 ($7.1) for 
extra-pulmonary and/1050.0($16.4) for extra pulmonary and 
pulmonary patients. Anti tubercular drugs and sputum test were free 
for patients who registered under RNTCP and so no expenses were 
incurred to the patients who were registered under DOTS strategy. 
One of the goals of RNTCP is that patient should not lose wages or 
incurs expenditure for travel. The travel expenses during diagnosis 
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were/67.5 ($16.3) for pulmonary,/84.6($1.3) extra pulmonary 
and/90($1.4) for extra-pulmonary and pulmonary tuberculosis. Our 
findings confirm that travel costs were lower as compared to study by 
Devra M Barter et al. [6]. 
 
Table 3: Direct cost incurred by tuberculosis patients 
Direct costs (cost in rupees) Pulmonary Extra-pulmonary Pulmonary and Extra-pulmonary 
Mean/($) Mean/($) Mean/($) 
i) Medical cost    
Hospital stay and visit  2156.3(33.6) 5476.8 (85.4) 6666.7(104.0) 
Administrative fees  
(consultation costs and patient registration fees) 
140.4(2.2) 171.8 (2.6) 438.3(6.8) 
Expenditure on Investigation   
i) lab examination 
During diagnosis 465.8 (7.3) 670 ($10.5) 943.2(14.7)  
During treatment 282.0 (4.4) 1209.1($18.8) 2106.8(32.9) 
Total 747.8 (11.7) 1879.1 ($29.3) 3050.0(47.6)  
ii)X-ray examination 
During diagnosis 240(3.7) 390 ($6.1) 430 (6.7)  
During treatment 807.9(12.6) 743.7 ($11.6) 861.6 (13.4) 
Total 1047.9 (16.3) 1133.7 ($17.7) 1291.6(20.1)  
Cost of medication other than tuberculosis drugs  
(including nutritional supplements) 
359.4 (5.6) 454.7 ($7.1) 1050.0(16.4)  
ii) Non medical cost    
Cost for travel during diagnosis  67.5 (1.1)  84.6(1.3) 90(1.4) 
Cost for food During diagnosis 203.1 (3.2) 530.2 (8.3) 1216.6(19.0) 
It was found that mean loss of income for pulmonary was 284.4($4.4) and loss of income by accompanying person was 467.6($7.3) for Extra 
pulmonary the mean loss of income was/326.7 ($5.1) and loss of income by accompanying person was/517.2 ($8.1) and mean loss of income for 
Pulmonary and Extra pulmonary patients was/835.3($13.0)  
 
Table 4: In direct cost incurred by tuberculosis patients 
In direct costs (cost in rupees) Pulmonary Extra-pulmonary  Pulmonary and extra pulmonary 
Mean/($) Mean/($) Mean/($) 
Loss of income during diagnosis 284.4($4.4) 326.7 ($5.1)  835.3($13.0) 
Loss of income by accompanying person during diagnosis  467.6($7.3) 517.2 ($8.1) - 
39.2% of working patients lose working days on account of diagnosis and hospitalization 
 
 
Fig. 1: Distribution of types of tuberculosis 
The mean total cost for Pulmonary tuberculosis treatment was 
found to be/5474.4 ($85.4), Extra pulmonary was/10574.8($164.9) 
and Pulmonary and Extra-pulmonary was/14638.5 ($228.3). 
 
Fig. 2: Loss of working days during TB detection (student and 
employed patients) 
The employed patients of pulmonary were 21 patients; 16 with 
extra-pulmonary and 3 with pulmonary and extra-pulmonary. The 
earning ability of pulmonary tuberculosis, extra-pulmonary 
tuberculosis and pulmonary and extra-pulmonary was 52.4 %, 68.7 
% and 66.7 % respectively. 
 
Fig. 3: Occupational disability due to TB 
 
The proportion of total cost in relation to annual family income was 
computed for all patients. The patients with annual income of 
50,000-1.20 lakhs spent 19.8% of their family annual income for 
tuberculosis detection and treatment. 
 
 
Fig. 4: Proportion of cost of tuberculosis therapy to annual 
family income 
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Indirect costs were classified as loss of wages due to illness, 
decreased earning ability due to illness or long term disability that 
necessitated change in type of work was calculated for 97 patients. 
In our study loss of income for pulmonary was 284.4 ($4.4) and loss 
of income by accompanying person was 467.6($7.3) for Extra-
pulmonary the mean loss of income was/326.7($5.1) and loss of 
income by accompanying person was 517.2 ($8.1) and mean loss of 
income for Pulmonary and Extra-pulmonary patients was/835.3 
($13.0). Of all 60.8% of working patient did not lose work days on 
account of illness which is quite similar to result study conducted by 
M. Muniyandi et al. [7]. Several other studies indicated that having 
TB had consequences for work [8]. 
The proportion of total cost in relation to annual family income was 
computed for all patients. The patients with annual income of 
50,000-1.20 lakhs spent 19.8% of their annual income for TB 
detection and treatment and our findings were similar to that of a 
study done by Ramya Ananthakrishnan et al. [9]. As reviewed by 
Russell S [10] the household financial burden would be catastrophic 
in developing countries if the total incurred cost of TB is more than 
10% of annual household income. 
CONCLUSION 
RNTCP has proven to be cost effective health intervention. The most 
expenses for tuberculosis treatment were related to hospitalization 
which incurred in pulmonary and extra pulmonary tuberculosis 
patients. In cases where the disease was diagnosed on time, costs 
were relatively low. Whereas, delay in disease diagnosis led to the 
worsening of the disease. If government can approve new scheme 
free of cost for diagnosing tuberculosis, which can help in reducing 
patients total cost of therapy.  
Our study concludes that DOTS strategy can help to reduce cost, 
achieve effective cure and save life of TB patients, especially among 
the poor, enabling them to return to work at the earliest, thus 
increasing their productivity. 
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